McMillan Office’s Ingevity NGVT Stock Holding History

McMillan Office’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.4K	Hold	216	–	–	﹤0.01%	366
2025 Q4	$12.8K	Buy	+216	New	+$11.7K	﹤0.01%	369

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

SCM

Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return

McMillan Office's NGVT Position: Q1 2026 in Review

McMillan Office held its Ingevity (NGVT) position steady in Q1 2026 at 216 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #366.

McMillan Office first reported a position in NGVT in Q4 2025 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.

McMillan Office held 216 shares of Ingevity worth $15.4K as of Q1 2026.
McMillan Office left its Ingevity share count unchanged in Q1 2026.
Ingevity made up ﹤0.01% of McMillan Office's portfolio in Q1 2026, its #366 holding.
McMillan Office first reported a position in Ingevity in Q4 2025 and has held it in 2 quarters since.
307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.

Based on McMillan Office's 13F filing for Q1 2026, filed 23 Apr 2026.